AU2017252126B2 - Use of thyroid beta-agonists - Google Patents
Use of thyroid beta-agonists Download PDFInfo
- Publication number
- AU2017252126B2 AU2017252126B2 AU2017252126A AU2017252126A AU2017252126B2 AU 2017252126 B2 AU2017252126 B2 AU 2017252126B2 AU 2017252126 A AU2017252126 A AU 2017252126A AU 2017252126 A AU2017252126 A AU 2017252126A AU 2017252126 B2 AU2017252126 B2 AU 2017252126B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- group
- alkyl
- day
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| US62/326,436 | 2016-04-22 | ||
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017252126A1 AU2017252126A1 (en) | 2018-11-08 |
| AU2017252126B2 true AU2017252126B2 (en) | 2023-02-09 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017252126A Active AU2017252126B2 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (enExample) |
| EP (1) | EP3445373B1 (enExample) |
| JP (1) | JP6931042B2 (enExample) |
| KR (1) | KR102407059B1 (enExample) |
| AU (1) | AU2017252126B2 (enExample) |
| BR (1) | BR112018071586A2 (enExample) |
| CA (1) | CA3021681C (enExample) |
| ES (1) | ES2992773T3 (enExample) |
| MX (1) | MX385085B (enExample) |
| WO (1) | WO2017185087A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445373B1 (en) | 2016-04-22 | 2024-08-21 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| KR20200138283A (ko) * | 2018-03-22 | 2020-12-09 | 바이킹 테라퓨틱스 인코포레이티드 | 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법 |
| EP3890747A4 (en) | 2018-12-05 | 2022-08-03 | Viking Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| JP2007524656A (ja) | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
| EP1689383B1 (en) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| BRPI0520207A2 (pt) | 2004-12-08 | 2012-09-25 | Revision Therapeutics Inc | uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado |
| MX2007014501A (es) * | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen acido fosfinico. |
| CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| JPWO2007097289A1 (ja) | 2006-02-20 | 2009-07-16 | 武田薬品工業株式会社 | 新規医薬 |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| CN107201364A (zh) | 2011-06-21 | 2017-09-26 | 阿尔尼拉姆医药品有限公司 | 用于抑制载脂蛋白c‑iii（apoc3）基因表达的组合物与方法 |
| JP2016517883A (ja) | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
| EP3259246B1 (en) | 2015-02-20 | 2023-03-22 | Oregon Health & Science University | Derivatives of sobetirome |
| EP3423379B1 (en) | 2016-02-29 | 2020-04-01 | Philip Morris Products S.a.s. | Hinge-lid container and blank |
| MX2018012904A (es) | 2016-04-22 | 2019-01-31 | Viking Therapeutics Inc | Uso de beta-agonistas del receptor de la hormona tiroidea. |
| EP3445373B1 (en) | 2016-04-22 | 2024-08-21 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| CN109475121B (zh) | 2016-05-18 | 2021-06-25 | 俄勒冈健康科学大学 | 苏比替罗衍生物 |
-
2017
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
Non-Patent Citations (1)
| Title |
|---|
| GENIN, E. C. ET AL.: "Induction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics", THE JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2009) vol. 116, no. 1, 31 August 2009 (2009-08-31), pages 37 - 43 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018012900A (es) | 2019-07-01 |
| BR112018071586A2 (pt) | 2019-02-12 |
| JP6931042B2 (ja) | 2021-09-01 |
| KR20190039027A (ko) | 2019-04-10 |
| US12440502B2 (en) | 2025-10-14 |
| EP3445373B1 (en) | 2024-08-21 |
| JP2019515033A (ja) | 2019-06-06 |
| MX385085B (es) | 2025-03-14 |
| WO2017185087A1 (en) | 2017-10-26 |
| US20220257618A1 (en) | 2022-08-18 |
| KR102407059B1 (ko) | 2022-06-10 |
| US11951114B2 (en) | 2024-04-09 |
| ES2992773T3 (en) | 2024-12-18 |
| US20250000880A1 (en) | 2025-01-02 |
| CA3021681A1 (en) | 2017-10-26 |
| EP3445373A4 (en) | 2019-12-18 |
| US11351183B2 (en) | 2022-06-07 |
| US20190321379A1 (en) | 2019-10-24 |
| AU2017252126A1 (en) | 2018-11-08 |
| CA3021681C (en) | 2024-09-24 |
| EP3445373A1 (en) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023202321B2 (en) | Use of thyroid beta-agonists | |
| US12440502B2 (en) | Use of thyroid beta-agonists | |
| AU2015274361B2 (en) | Combination therapy with glutaminase inhibitors | |
| KR102220175B1 (ko) | 헤테로사이클릭 글루타미나아제 억제제 | |
| KR20190125432A (ko) | 글루타미나제 억제제를 사용하는 병용 요법 | |
| UA123700C2 (uk) | Композиції і способи інгібування активності аргінази | |
| US11382908B2 (en) | Compositions and methods for treating inflammatory bowel disease | |
| EP3692052A1 (en) | Small molecule inhibition of transcription factor sall4 and uses thereof | |
| HK40064933A (en) | Use of thyroid beta-agonists | |
| HK40013781A (en) | Use of thyroid beta-agonists | |
| HK40007271A (en) | Use of thyroid beta-agonists | |
| HK40013781B (zh) | 甲状腺β-激动剂的应用 | |
| WO2023211843A1 (en) | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions | |
| WO2017127417A1 (en) | Phosphopantothenate compounds | |
| CN108289899A (zh) | 采用葡萄糖生成的抑制剂的联合疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: VIKING THERAPEUTICS, INC. Free format text: FORMER NAME(S): VIKING THERAPEUTICS, INC.; METABASIS THERAPEUTICS, INC; HONGJIAN JIANG Owner name: METABASIS THERAPEUTICS, INC. Free format text: FORMER NAME(S): VIKING THERAPEUTICS, INC.; METABASIS THERAPEUTICS, INC; HONGJIAN JIANG |
|
| FGA | Letters patent sealed or granted (standard patent) |